Takeda

Key TakeawaysThe President's recommendation supports the reimbursement of Adderall XR for attention deficit hyperactivity disorder treatment. The decision aims to improve access to...

Key TakeawaysTakeda's FRUZAQLA (fruquintinib), an innovative targeted therapy, has been approved in Japan for unresectable advanced colorectal cancer. The approval is based on...

Key Takeaways:Lupin Limited has signed a non-exclusive patent license agreement with Takeda Pharmaceutical Company to commercialize Vonoprazan Tablets in the Indian market under...

Key TakeawaysAlkem Laboratories has entered a landmark licensing agreement with Takeda Pharmaceutical Company to commercialize Vonoprazan, a novel medication for gastrointestinal disorders, in...

Takeda has received European Commission approval for ADZYNMA® (recombinant ADAMTS13), making it the first and only recombinant enzyme replacement therapy available for congenital thrombotic...

Results from Takeda (TOKYO:4502/NYSE) were announced today, detailing earnings for the first quarter of fiscal year 2024 (period ended June 30, 2024). The company...

Takeda Pharmaceuticals has announced encouraging results from its Phase 2b study of mezagitamab, showing potential to transform the treatment of primary immune thrombocytopenia (ITP)....

Takeda has announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved LIVTENCITY® (maribavir) for treating post-transplant cytomegalovirus (CMV) infection/disease refractory to...

Takeda has presented favorable data from the Phase 3 ADVANCE-CIDP 3 clinical trial, a long-term study evaluating HYQVIA® for chronic inflammatory demyelinating polyneuropathy...

In a significant move within the pharmaceutical industry, Takeda and Ascentage Pharma have signed an option agreement for the development and commercialization of olverembatinib,...